Microneedling live bacteria: Crown Aesthetics marks “significant milestone” in dermatology
(All Image Credits: Crown Aesthetics).15 Dec 2023 --- In a “groundbreaking” exploration, a subsidiary of Crown Laboratories, Crown Aesthetics, discovers the impact of its Biojuve regimen for skin-biome care, particularly for acne treatments. A recent clinical study in the Journal of Clinical and Aesthetic Dermatology shows the synergy between living microbes and skin remodeling.
Led by Dr. Thomas Hitchcock, Crown’s chief science officer, the team developed Biojuve, a living microbe technology that harnesses the live strain Cutibacterium acnes defendens (C. acnes defendens). It is said to optimizes skin health for a range of anti-aging concerns.
Microbiome-optimized approach
Lead investigator Dr. Mona L. Alqam spearheaded the clinical study, which focused on the aftermath of SkinPen Precision microneedling, a popular aesthetic procedure. SkinPen Precision is the first FDA-cleared microneedling system.
According to Crown Aesthetics, SkinPen is the First FDA-cleared microneedling device in the world.
The study enrolled 40 participants with acne scars, divided into two groups. Group one followed the Biojuve regimen with live C. acnes defendens strain XYCM42, while Group two adhered to a conventional skin care routine.
Participants in Group one, following the Biojuve regimen, exhibited a statistically significant difference in overall aesthetic improvement. This was assessed using the Clinician’s Global Aesthetic Improvement Scale (CGAIS).
Notably, the study showcased a positive trend in photo grading for CGAIS. Group one participants also reported a quicker decline in post-treatment symptoms, including erythema, swelling, burning or tingling and itching.
“Integrating a microbiome-optimized, probiotic XYCM42 regimen with the SkinPen microneedling procedure demonstrated enhanced treatment experience. This study marks a significant milestone in aesthetic dermatology, paving the way for innovative microbiome-based approaches to improve skin health pre and post-popular aesthetic treatments,” comments Mona L. Alqam, MD, global VP of Medical and Clinical Affairs at Crown Laboratories.
A previous study on Crown Laboratories’ patented Xycrobe technology highlighted the growing evidence reinforcing that human health depends on symbiosis with its skin microflora.
Edited by Venya Patel
